a b s t r a c t Sarcopenia, the age-related loss of skeletal muscle mass, is a significant public health concern that continues to grow in relevance as the population ages. Certain conditions have the strong potential to coincide with sarcopenia to accelerate the progression of muscle atrophy in older adults. Among these conditions are co-morbid diseases common to older individuals such as cancer, kidney disease, diabetes, and peripheral artery disease. Furthermore, behaviors such as poor nutrition and physical inactivity are well-known to contribute to sarcopenia development. However, we argue that these behaviors are not inherent to the development of sarcopenia but rather accelerate its progression. In the present review, we discuss how these factors affect systemic and cellular mechanisms that contribute to skeletal muscle atrophy. In addition, we describe gaps in the literature concerning the role of these factors in accelerating sarcopenia progression. Elucidating biochemical pathways related to accelerated muscle atrophy may allow for improved discovery of therapeutic treatments related to sarcopenia.
Introduction
Sarcopenia, the age-related loss of muscle mass and quality, is a major healthcare concern for older adults (Fig. 1) . The condition is associated with the development of functional disability (Janssen et al., 2004; Visser et al., 2005) and may lead to the loss of independence for afflicted individuals. Because of the costs associated with caring for an individual with compromised function, sarcopenia has been linked to elevated healthcare costs (Janssen et al., 2004) .
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* Moreover, the absolute costs associated with sarcopenia are likely to rise sharply in the coming decades considering that the total number of persons over 65 years is expected to double over the next 25 years (Federal Interagency Forum on Aging-Related Statistics, 2009). Hence, additional knowledge of mechanisms underlying sarcopenia development is necessary to advance prevention and treatment efforts that will improve the quality of life for millions of older adults.
Need for a standardized definition
Currently, clinical awareness of the signs and consequences of sarcopenia is lacking. This problem stems, at least partially, from the absence of an established clinical definition of sarcopenia (Visser, 2009 ) which precludes medical diagnosis of the condition. Without a definition, the ability of physicians to recognize and appropriately treat sarcopenia will remain poor. Previously, this same challenge faced clinicians treating patients with cachexia (Evans et al., 2008) . In addition to these clinical difficulties, the absence of a universally-accepted definition of sarcopenia creates challenges for investigators studying the underlying causes of the condition. Presently, scientists disagree on whether sarcopenia refers only to age-related muscle atrophy as it was originally proposed (Roubenoff and Hughes, 2000) , or whether muscle function -i.e. strength and endurance -should be included as part of the definition (Clark and Manini, 2008; Visser, 2009 ). Muscle function is clearly the critical step that links sarcopenia to func-
